$TRVN can rise in the next daysContextual immersion trading strategy idea.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system.
The demand for shares of the company still looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $1,66;
stop-loss — $1,54.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Biotech
Will LPCN Break back Above Previous Support Or...or will it become resistance? There's been a lot of momentum building up ever since LPCN fell off. We saw some insider buying this month but no new news. Meanwhile other companies are presenting at virtual conferences and all that. It makes you wonder if LPCN has enough steam to reclaim its old levels or if this is just a speculation-driven move in the short term.
"In May Lipocine received RDA clearance for an investigational new drug application for a Phase 2 study of LPCN 1148. This is a prodrug of bioidentical testosterone to treat liver cirrhosis. Furthermore, the company reported results of a preclinical study of its LPCN 1144 which demonstrated encouraging results according to the company. H.C. Wainright took notice of these milestones and increased its price target on LPCN stock to $3 while maintaining a Buy rating."
Quote Source & Info: Can You Make Money With Penny Stocks? 3 Up Big In June
$RETA can rise in the next daysContextual immersion trading strategy idea.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
The demand for shares of the company still looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $175,59;
stop-loss — $173,13.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
VRTX : SLINGSHOT125% earnings growth past quarter, +30% previous quarters
+76% revenue growth past quarter, accelerating from the precious quarters
Positive earnings revisions
Biotech Looking a Little Sick: LABDAnother descending triangle has appeared in LABD. My numerous other finds have yielded decent results but we have yet to see a turn in the market indicating a new direction. The play itself might be worth a couple of percent gain but please trade safely. The downturn near the end of Friday's session is forecasting a likely poor Monday opening in addition to the negative news that continues to come out of the ECB and New York.
$FMTX is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $43,24;
take-profit — $57,88;
stop-loss — $38,36.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
PHARMING LONG termHello all,
Here another TA of me, this time on the stock PHARMING.
Its a very interesting company, i would advice you to dive in the fundamentals for further information. I will just show the possibilities with TA.
Before you choose to buy and hold a stock, always do your homework on the fundamentals. TA can help you by choosing a good moment and price to buy the stock.
PHARMING is fundamental a healthy company and one of a kind. If you are interested in a possible gem, please check out the fundamentals and see it for yourself.
From TA perspective, price is moving into a triangle/flag pattern and 'soon' have to choose direction. Personaly I'm thinking it can go both ways.
But with stocks, and specialy the ones you want to hold for long term, you just have to check out the fundamentals.
I do not recommend this stock for daytrading, although there are possibilities. As you can see the jump earlier after the news of 5 people who have bin treated with their medicine, RUCONEST, pure doing analysis on the chart on this stock is a bit hard and tricky in my opinion. You just never know when there will be published some news what will effect the price big time.
Personally i do think the current price can be a good moment to start buying this stock for the LONG term. Buy and Hold.
This is just my view and opinion and in the end you always decide for yourself .
Don't ever go blind on someone else his vision, create one for your self!
Have fun and good luck trading. :)
Bullish Charts - Acacia Buys Stake in 19 CompaniesAcacia Research Corporation, together with its subsidiaries, invests in intellectual property and related absolute return assets; and engages in the licensing and enforcement of patented technologies. It assists patent owners with the prosecution and development of their patent portfolios; protection of their patented inventions from unauthorized use; generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. The company owns or controls the rights to various patent portfolios, which include U.S. patents and foreign counterparts covering technologies used in a range of industries. It has executed approximately 1,570 license agreements, and approximately 200 patent portfolio licensing and enforcement programs. Acacia Research Corporation was founded in 1993 and is headquartered in Irvine, California.
On 6/5/2020, Acacia agreed to acquire a portfolio of Life Science Assets for $283 Million
The transaction allows Acacia to purchase shares in up to 19 public and private life sciences companies.
Lets see where this one goes now.
Looks undervalued at current levels.
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Covid funding p&dThis company has not done anything noteworthy for the last few years. They were able to get funding from the European International Bank to work on COVID related solutions released in 3 tranches. The likely outcome is they will not make enough progress to unlock the future tranches. Seems to me like they are just grabbing the handout and will resume their normal downtrend in the long term.
BNR is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Burning Rock Biotech Limited focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $24,54;
take-profit — $32,74;
stop-loss — $21,82.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
RNA is giving a GREAT IPO LONG opportunity today IPO intraday trading strategy idea
Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $28,4;
take-profit — $38,12
stop-loss — $25,16
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Moderna seeing positive OBV divergence Looks like NASDAQ:MRNA is set for a bullish trend. The OBV has made new highs on lower price points.
"Volume precedes Price"
GBIO is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
Generation Bio is an innovative genetic medicine company creating a new class of gene therapy.
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $23,31;
take-profit — $28,53;
stop-loss — $21,57.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Largest owner in Photocure $PHO.OL offloading whole positionLargest owner in Photocure OSL:PHO apparently being forced to dump the whole position in the stock in the course of a few days, giving the stock extra momentum to the downside.
Updated list of shareholders show influx of US actors.
twitter.com
$ATOS can rise in the next daysContextual immersion trading strategy idea.
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States.
The share price rose after announcing the availability of the CEO's 158-page book "Your COVID-19 Survival Manual: A Physician's Guide to Keep You and Your Family Healthy During the Pandemic and Beyond"
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $3,21;
stop-loss — $3,08.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
CVM About to Start New RallyWeekly Chart :
AMEX:CVM Finished the Major Down Trend on April 2019, and from then is in a solid Secondary Up Trend.
Note 13.50 Historical level, which serve us as a good support to form a trade.
Daily Chart :
Minor Down Trend about to end (Yellow):
Line Chart :
The Trade Plan :
Wait for a Clear Bullish Minor sign -
1. Strong buying Candle on 13.50 Level .
2. Retest of the Orange Trendline and closing above the Yellow Trendline.
Only for investors : Biotech For those looking to diversify their portfolio or a long-term investment. Here I bring you an option in the biotech sector: Bluebird Bio INC, the leader in targeted cell therapy.
This stock is in an important support area. It is a zone where buyers will seek to accumulate to buy cheap. the risk in this operation is low compared to the profit potential
BIOTECH Bluebird BIOThe Stock stay very bullish, the volume increased strongly.
However the $72 level approaches. And it could be a good point of profit taking. Some corretions may come.
If break-out of the $72, then the $80 can be a good arrival point.
keep in touch!
VBIV target [$3.50] by July 1st Expect a significant appreciation in price leading up to the upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR virtual annual meeting.
Your charts are wrong?Are you looking at Price changes? Moves over time? What is it you want to see...?
Stuck with Candles looking for patterns?
Renko Blocks
Henken-Ashi
Kagi
$NTLA can rise in the next daysContextual immersion trading strategy idea.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
The share price rose after the company announced an expansion of its partnership with Regeneron Pharmaceuticals (REGN).
The pair will jointly develop drug candidates to treat hereditary blood disorders hemophilia A and hemophilia B. Additionally, Regeneron Pharmaceuticals will gain rights to develop drug candidates using both in vivo (inside the body) and ex vivo (outside the body) drug candidates and delivery tools developed by Intellia Therapeutics — www.fool.com
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $22,24;
stop-loss — $21,25.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
VBIV set for huge gains on Monday?It's too early for me to enter into a position here, but as WIN219 mentioned in his recent idea, an obvious Adam and Eve chart pattern is forming. If $2.36 - $2.40 price level holds up and the pattern completes, I will open a long position. This might be a great buy opportunity if the chart plays out.
